Russia's COVID-19 Vaccine Considered Safe in Early Human Trial: Lancet

Sputnik V, the COVID-19 vaccine, approved by Russia last month, has been shown to elicit an immune response with no serious side effects in small human trials, reports a new study. The findings of the study are published in the journal The Lancet. Sputnik V was registered by Russia last month, becoming the first country to approve a COVID-19 vaccine. However, the country encountered criticism for approving a vaccine before the completion of Phase-3 trials.

In the Lancet study, researchers reported on two small trials, each involving 38 healthy adults (aged 18-60 years), who were given a two-part immunization.

Each participant of the study was given the first part of the vaccine dose, followed by a booster. They monitored the participants over 42 days, and all developed antibodies within the first three weeks.

The vaccine was found to be safe, well tolerated, and does not cause serious unfavorable events in participants.

Phase-3 trial of the vaccine is being planned by Russia, involving 40,000 people.

Source-Medindia